Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1995 2
1996 1
1997 6
1998 19
1999 11
2000 12
2001 18
2002 22
2003 20
2004 25
2005 35
2006 31
2007 27
2008 37
2009 17
2010 20
2011 28
2012 21
2013 21
2014 19
2015 17
2016 13
2017 11
2018 9
2019 10
2020 8
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

423 results
Results by year
Filters applied: . Clear all
Page 1
Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease.
Haynes R, Judge PK, Staplin N, Herrington WG, Storey BC, Bethel A, Bowman L, Brunskill N, Cockwell P, Hill M, Kalra PA, McMurray JJV, Taal M, Wheeler DC, Landray MJ, Baigent C. Haynes R, et al. Circulation. 2018 Oct 9;138(15):1505-1514. doi: 10.1161/CIRCULATIONAHA.118.034818. Circulation. 2018. PMID: 30002098 Clinical Trial.
RESULTS: In total, 207 participants were assigned to sacubitril/valsartan and 207 to irbesartan. Baseline measured GFR was 34.0 (SE, 0.8) and 34.7 (SE, 0.8) mL/min/1.73 m(2), respectively. ...CONCLUSIONS: Over 12 months, sacubitril/valsartan has similar effects on kidney f …
RESULTS: In total, 207 participants were assigned to sacubitril/valsartan and 207 to irbesartan. Baseline measured GFR was 34.0 (SE, …
Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial.
Mullen M, Jin XY, Child A, Stuart AG, Dodd M, Aragon-Martin JA, Gaze D, Kiotsekoglou A, Yuan L, Hu J, Foley C, Van Dyck L, Knight R, Clayton T, Swan L, Thomson JDR, Erdem G, Crossman D, Flather M; AIMS Investigators. Mullen M, et al. Lancet. 2019 Dec 21;394(10216):2263-2270. doi: 10.1016/S0140-6736(19)32518-8. Epub 2019 Dec 10. Lancet. 2019. PMID: 31836196 Free PMC article. Clinical Trial.
We aimed to determine the effects of irbesartan on the rate of aortic dilatation in children and adults with Marfan syndrome. ...Irbesartan was well tolerated with no observed differences in rates of serious adverse events. ...
We aimed to determine the effects of irbesartan on the rate of aortic dilatation in children and adults with Marfan syndrome. ...I
DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS.
Trachtman H, Nelson P, Adler S, Campbell KN, Chaudhuri A, Derebail VK, Gambaro G, Gesualdo L, Gipson DS, Hogan J, Lieberman K, Marder B, Meyers KE, Mustafa E, Radhakrishnan J, Srivastava T, Stepanians M, Tesar V, Zhdanova O, Komers R; DUET Study Group. Trachtman H, et al. J Am Soc Nephrol. 2018 Nov;29(11):2745-2754. doi: 10.1681/ASN.2018010091. J Am Soc Nephrol. 2018. PMID: 30361325 Free PMC article. Clinical Trial.
The FSGS partial remission end point was achieved in 28% of sparsentan-treated and 9% of irbesartan-treated patients (P=0.04). After 8 weeks of treatment, BP was reduced with sparsentan but not irbesartan, and eGFR was stable with both treatments. ...CONCLUSIONS: Pa …
The FSGS partial remission end point was achieved in 28% of sparsentan-treated and 9% of irbesartan-treated patients (P=0.04). After …
Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.
Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J. Oparil S, et al. J Clin Hypertens (Greenwich). 2001 Sep-Oct;3(5):283-91, 318. doi: 10.1111/j.1524-6175.2001.01136.x. J Clin Hypertens (Greenwich). 2001. PMID: 11588406 Free article. Clinical Trial.
The reduction of sitting cuff DBP with olmesartan (11.5 mm Hg), the primary efficacy variable of this study, was significantly greater than with losartan, valsartan, and irbesartan (8.2, 7.9, and 9.9 mm Hg, respectively). Reductions of cuff SBP with the four ARBs ranged fr …
The reduction of sitting cuff DBP with olmesartan (11.5 mm Hg), the primary efficacy variable of this study, was significantly greater than …
Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III-rationale, trial design and baseline data.
UK HARP-III Collaborative Group. UK HARP-III Collaborative Group. Nephrol Dial Transplant. 2017 Dec 1;32(12):2043-2051. doi: 10.1093/ndt/gfw321. Nephrol Dial Transplant. 2017. PMID: 27646835 Free PMC article. Clinical Trial.
METHODS: UK Heart and Renal Protection III (HARP-III) is a multicentre, double-blind, randomized controlled trial comparing sacubitril/valsartan 97/103 mg two times daily (an angiotensin receptor-neprilysin inhibitor) with irbesartan 300 mg one time daily among 414 patient …
METHODS: UK Heart and Renal Protection III (HARP-III) is a multicentre, double-blind, randomized controlled trial comparing sacubitril/valsa …
Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction.
Tromp J, Shen L, Jhund PS, Anand IS, Carson PE, Desai AS, Granger CB, Komajda M, McKelvie RS, Pfeffer MA, Solomon SD, Køber L, Swedberg K, Zile MR, Pitt B, Lam CSP, McMurray JJV. Tromp J, et al. J Am Coll Cardiol. 2019 Aug 6;74(5):601-612. doi: 10.1016/j.jacc.2019.05.052. J Am Coll Cardiol. 2019. PMID: 31370950 Free article. Clinical Trial.
METHODS: Using data on patients with left ventricular ejection fraction 45% from 3 large HFpEF trials (TOPCAT [Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function], I-PRESERVE [Irbesartan in Heart Failure With Preserved Systolic Fun …
METHODS: Using data on patients with left ventricular ejection fraction 45% from 3 large HFpEF trials (TOPCAT [Aldosterone Antagonist Therap …
Irbesartan in patients with heart failure and preserved ejection fraction.
Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A; I-PRESERVE Investigators. Massie BM, et al. N Engl J Med. 2008 Dec 4;359(23):2456-67. doi: 10.1056/NEJMoa0805450. Epub 2008 Nov 11. N Engl J Med. 2008. PMID: 19001508 Free article. Clinical Trial.
RESULTS: During a mean follow-up of 49.5 months, the primary outcome occurred in 742 patients in the irbesartan group and 763 in the placebo group. Primary event rates in the irbesartan and placebo groups were 100.4 and 105.4 per 1000 patient-years, respectively (ha …
RESULTS: During a mean follow-up of 49.5 months, the primary outcome occurred in 742 patients in the irbesartan group and 763 in the …
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. Lewis EJ, et al. N Engl J Med. 2001 Sep 20;345(12):851-60. doi: 10.1056/NEJMoa011303. N Engl J Med. 2001. PMID: 11565517 Free article. Clinical Trial.
The risk of a doubling of the serum creatinine concentration was 33 percent lower in the irbesartan group than in the placebo group (P=0.003) and 37 percent lower in the irbesartan group than in the amlodipine group (P<0.001). Treatment with irbesartan was …
The risk of a doubling of the serum creatinine concentration was 33 percent lower in the irbesartan group than in the placebo group ( …
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. Parving HH, et al. N Engl J Med. 2001 Sep 20;345(12):870-8. doi: 10.1056/NEJMoa011489. N Engl J Med. 2001. PMID: 11565519 Free article. Clinical Trial.
We evaluated the renoprotective effect of the angiotensin-II-receptor antagonist irbesartan in hypertensive patients with type 2 diabetes and microalbuminuria. ...Serious adverse events were less frequent among the patients treated with irbesartan (P=0.02). CONCLUSI …
We evaluated the renoprotective effect of the angiotensin-II-receptor antagonist irbesartan in hypertensive patients with type 2 diab …
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Pfeffer M, Hohnloser S, Yusuf S. ACTIVE Writing Group of the ACTIVE Investigators, et al. Lancet. 2006 Jun 10;367(9526):1903-12. doi: 10.1016/S0140-6736(06)68845-4. Lancet. 2006. PMID: 16765759 Clinical Trial.
423 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page